Heterozygous Familial Hypercholesterolemia Management Global Market Report 2025

The heterozygous familial hypercholesterolemia management market size has grown rapidly in recent years. It will grow from $10.84 billion in 2024 to $12.07 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth during the historic period can be attributed to the increasing prevalence of cardiovascular diseases, government initiatives, rising investment in research and development activities, greater awareness and diagnosis of HeFH, and the growing demand for personalized therapies.

The heterozygous familial hypercholesterolemia management market size is expected to see rapid growth in the next few years. It will grow to $18.37 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth during the forecast period can be attributed to the expansion of telehealth services, the rising prevalence of chronic illnesses, the increasing number of clinical trials, the growing geriatric population, and the surge in drug pipeline developments. Key trends in the forecast period include the integration of digital health solutions, advancements in therapeutic options, the development of combination therapies, technological innovations, and the emergence of novel treatments.

The increasing prevalence of cardiovascular diseases is expected to drive the expansion of the heterozygous familial hypercholesterolemia management market. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The growing incidence of CVDs worldwide is linked to rising risk factors such as unhealthy diets, sedentary lifestyles, obesity, and an aging population. Effective management of heterozygous familial hypercholesterolemia plays a vital role in preventing cardiovascular diseases by controlling high cholesterol levels, a major risk factor for atherosclerosis and heart-related complications. For example, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, approximately 805,000 people in the United States suffered a heart attack in 2022, with 605,000 being first-time cases and 200,000 occurring in individuals with a previous history of heart attacks. As a result, the rising prevalence of cardiovascular diseases is fueling the growth of the heterozygous familial hypercholesterolemia management market.

Leading companies in the heterozygous familial hypercholesterolemia management market are focusing on developing innovative treatments, such as angiopoietin-based therapies, to improve lipid metabolism and lower cholesterol levels. Angiopoietins are a family of proteins that regulate blood vessel formation (angiogenesis) and maintain vascular stability. For instance, in March 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Evkeeza (evinacumab-dgnb) for children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). This first-in-class monoclonal antibody works by inhibiting ANGPTL3, a protein that disrupts lipid metabolism, thereby reducing low-density lipoprotein (LDL) cholesterol and triglyceride levels. This approval provides a novel therapeutic option for pediatric patients with limited treatment alternatives and a high risk of cardiovascular events.

In February 2025, Tempus AI Inc., a US-based testing laboratory company, acquired Ambry Genetics for an undisclosed amount. This acquisition aims to enhance diagnostics and patient care by integrating artificial intelligence with genetic testing and expanding into new disease areas. Ambry Genetics Corporation, a US-based company, specializes in genetic testing for heterozygous familial hypercholesterolemia (HeFH).

Major players in the heterozygous familial hypercholesterolemia management market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Ipsen S.A., Chiesi Farmaceutici S.p.A., Ferring Pharmaceuticals Limited, Esperion Therapeutics Inc., Aegerion Pharmaceuticals Inc., Verve Therapeutics Inc.

North America was the largest region in the heterozygous familial hypercholesterolemia management market in 2024. The regions covered in heterozygous familial hypercholesterolemia management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the heterozygous familial hypercholesterolemia management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Heterozygous familial hypercholesterolemia (HeFH) management is a comprehensive strategy aimed at controlling elevated low-density lipoprotein cholesterol (LDL-C) levels in individuals with a genetic predisposition to high cholesterol. The goal is to lower the risk of premature cardiovascular disease (CVD) through lifestyle modifications, lipid-lowering medications, and, in certain cases, advanced treatments such as lipoprotein apheresis.

The primary treatment options for HeFH management include statins, ezetimibe, PCSK9 inhibitors, lomitapide, and mipomersen. Statins are a class of medications that lower cholesterol levels by inhibiting HMG-CoA reductase, a key enzyme in cholesterol production in the liver. The available routes of administration include oral, injectable, and intravenous. The treatment applies to various patient demographics, including children, adults, and the elderly, and is utilized in multiple healthcare settings such as hospitals, medical centers, clinics, and others.

The heterozygous familial hypercholesterolemia management market research report is one of a series of new reports that provides heterozygous familial hypercholesterolemia management market statistics, including the heterozygous familial hypercholesterolemia management industry global market size, regional shares, competitors with the heterozygous familial hypercholesterolemia management market share, detailed heterozygous familial hypercholesterolemia management market segments, market trends, and opportunities, and any further data you may need to thrive in the heterozygous familial hypercholesterolemia management industry. This heterozygous familial hypercholesterolemia management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The heterozygous familial hypercholesterolemia management market includes revenues earned by entities by providing services such as genetic testing and diagnosis, cholesterol monitoring, and lifestyle counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.